Myeloproliferative neoplasm pathophysiology: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 4: Line 4:


==Overview==
==Overview==
Clinical and pathologic findings in the myeloproliferative neoplasms (MPNs) are due to dysregulated proliferation and expansion of [[myeloid]] progenitors in the [[bone marrow]], resulting in altered populations of [[granulocytes]], [[erythrocytes]], or [[platelets]] in the peripheral blood.
Clinical and pathologic features in the myeloproliferative neoplasms are due to dysregulated proliferation and expansion of [[myeloid]] [[progenitors]] in the [[bone marrow]], resulting in altered populations of [[granulocytes]], [[erythrocytes]], or [[platelets]] in the peripheral blood.


==Pathophysiology==
==Pathophysiology==
Line 34: Line 34:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Oncology]]

Revision as of 21:52, 1 April 2015

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm pathophysiology

on Myeloproliferative neoplasm pathophysiology

Myeloproliferative neoplasm pathophysiology in the news

Blogs on Myeloproliferative neoplasm pathophysiology

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Clinical and pathologic features in the myeloproliferative neoplasms are due to dysregulated proliferation and expansion of myeloid progenitors in the bone marrow, resulting in altered populations of granulocytes, erythrocytes, or platelets in the peripheral blood.

Pathophysiology

Reciprocal translocation associated with the Philadelphia chromosome. Adapted from National Cancer Institute.[1]

Genetics

Primary cytogenetic abnormalities have not been identified in the majority of myeloproliferative neoplasms. Aberrant activation of tyrosine kinases and associated signaling pathways is frequently implicated as the disease-initiating event.

Chronic Myelogenous Leukemia

In chronic myelogenous leukemia, a balanced reciprocal translocation termed t(9;22)(q34;q11.2) results in formation of the BCR-ABL hybrid gene which encodes for the p210BCR-ABL oncoprotein. Constitutive activation of the BCR-ABL oncogene and downstream signaling pathways confers survival advantage to leukemic cells and suppresses normal hematopoiesis.

Polycythemia Vera

In polycythemia vera, erythroid progenitors demonstrate hypersensitivity to insulin-like growth factor-1 (IGF-1) and other cytokines. Mutations in the Janus kinase 2 gene, particularly JAK2V617V, may contribute to cytokine-independent proliferation of CD34+ hematopoietic progenitors and their progeny.

Primary Myelofibrosis

Primary myelofibrosis is hallmarked by clonal myeloproliferation with reactive stromal changes in response to uncontrolled production of growth factors (e.g., transforming growth factor β, platelet-derived growth factor, and basic fibroblast growth factor) from resident megakaryocytes and monocytes. Etiopathogenic mutations leading to primary myelofibrosis remain unclear.[2]

References

  1. "Chronic Myelogenous Leukemia Treatment".
  2. Jaffe, Elaine (2001). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press Oxford University Press. ISBN 978-9283224112.